

Disclosure of trading in own shares

Paris (France), 14 May 2009 – Ipsen (Euronext: IPN) declares below the transactions made on its own shares for the period from 6 May 2009 until 13 May 2009.

Ipsen S.A.

a French company with a registered share capital of 84 059 683 €

Registered office: 65, quai Georges Gorse – 92100 Boulogne Billancourt (France)

Registered at the Nanterre Commercial and Companies Registry under number 419 838 529
RCS Nanterre

		Number of shares	Weighted Average Price (€)	Amount (€)
06/05/2009	Purchase	-	-	-
	Sale	-	-	-
07/05/2009	Purchase	13,591	31.032	421,750
	Sale	-	-	-
08/05/2009	Purchase	15,000	30.661	459,915
	Sale	-	-	-
11/05/2009	Purchase	30,000	30.626	918,793
	Sale	-	-	-
12/05/2009	Purchase	30,000	31.199	935,970
	Sale	-	-	-
13/05/2009	Purchase	30,000	31.781	953,430
	Sale	-	-	-
Total	Purchase	118,591	31.114	3,689,858

About Ipsen

Ipsen is an innovation-driven international specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty products, which are growth drivers, in targeted therapeutic areas (oncology, endocrinology and neurology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active policy of partnerships. In 2008, Research and Development expenditure was about €183 million, close to 19% of consolidated sales, which amounted to €971 million while total revenues exceeded €1 billion. Ipsen's shares are traded on Segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen's shares are eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of the SBF 120 index. For more information on Ipsen, visit our website at www.Ipsen.com.

For further information

Didier Véron

Director, Public Affairs and Corporate Communications

Tél.: +33 (0)1 58 33 51 16 / Fax: +33 (0)1 58 33 50 58

e-mail: didier.veron@ipsen.com

David Schilansky

Investor Relations and Financial Officer

Tél.: +33 (0)1 58 33 51 30

Fax: +33 (0)1 58 33 50 63

e-mail: david.schilansky@ipsen.com

Pierre Kemula

Investor Relations Manager

Tél.: +33 (0)1 58 33 60 08

Fax: +33 (0)1 58 33 50 63

e-mail: pierre.kemula@ipsen.com